NVSEF News and Press, Novartis Ag Basel Akt From 06/06/22

Disclosing data from a global Phase 2/3 trial, Novartis (NYSE:NVS) (OTCPK:NVSEF) announced on Monday that its drug combination of Tafinlar and Mekinist reduced the risk of disease progression or death for a type of childhood brain cancer by more than two thirds compared to chemotherapy. The t...

Results from the phase 2a INTEGRIS-PSC study using PLN-74809 for the treatment of patients with primary sclerosing cholangitis are expected 1st half of 2023. PLN-74809 is also being explored for the treatment of patients with idiopathic pulmonary fibrosis; Preliminary safety and effic...

QUVIVIQ (Daridorexant) and PIVLAZ (Clazosentan) are now commercialized by Idorisa, and Johnson & Johnson is distributing Ponvory (Ponesimod). The Swiss and Canadian health authorities are supposed to give their feedback on QUVIVIQ very soon. The stock price has been repeatedly...

Pharmaceuticals and biotechnology are cheap relative to 11-year valuation averages. Life science tools and healthcare equipment are overvalued. IXJ: a global alternative to XLV. 10 stocks cheaper than their peers in May. For further details see: IXJ: Healthcare Dashb...

Wolfe Research has lowered its rating on Novartis (NYSE:NVS) (OTCPK:NVSEF) to Peer Perform from Outperform, noting that the valuation of the Swiss pharma company has reached a level on par with those of its high growth peers. The analyst Tim Anderson argues that the recent uptick in Novartis ...

Fisher's 13F portfolio value decreased from ~$179B to ~$165B in Q1 2022. Nvidia, Intuit, Broadcom, Verizon, Uber, AMD, & Meta Platforms were increased while reducing Intel, Walmart, Walt Disney, Cisco, UnitedHealth, Starbucks & Visa this quarter. The top three positions ar...

Novartis (NYSE:NVS) (OTCPK:NVSEF) announced on Thursday that the company decided to pause production at its radioligand therapy manufacturing sites in Ivrea, Italy, and Millburn, New Jersey, after finding quality issues. The production halt has prompted the company to temporarily su...

Kahn Brothers’ 13F portfolio value increased from $741M to $788M this quarter. Citigroup, ViewRay, and VOXX International were increased during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~48% of the 13F holdings. ...

Chinese biotech BeiGene (NASDAQ:BGNE) announced on Wednesday that a Phase 3 trial for the company’s anti-PD-1 inhibitor tislelizumab in combination with chemotherapy reached primary endpoint in a group of patients with esophageal squamous cell carcinoma (ESCC). The 649-patient RATIONAL...

Novartis AG (NVS) Q1 2022 Earnings Conference Call April 26, 2022 08:00 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Graham Parry - Bank of America Simon ...